Actively Recruiting
Phase Ib Study of JSKN016 Combination Treatments for Advanced Non-Small Cell Lung Cancer in Adults
Led by Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Updated on 2026-03-30
288
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the treatment of advanced non-small cell lung cancer NSCLC using the drug JSKN016 in combination with other therapies. This Phase Ib clinical study is conducted in China and includes participants with locally advanced or metastatic NSCLC who are not suitable for radical surgery or radiotherapy. The main goal is to assess both the effectiveness and safety of JSKN016 combined with various treatments in this patient group. Participants receive JSKN016 alongside one of several other drugs including carboplatin, furmonertinib mesylate tablets, ivonescimab, docetaxel, tislelizumab, or pembrolizumab. These medications are given intravenously or orally at specified doses outlined in the study protocol. There are multiple treatment cohorts, each receiving different combinations to evaluate various therapeutic approaches. During the study, participants will undergo regular assessments for tumor response using standardized criteria RECIST v1.1 and monitoring of any side effects. Safety and plasma drug levels will be measured for up to 24 months. The study also tracks progression-free survival, overall survival, and other clinical outcomes. Participants are expected to be involved in scheduled visits and tests for up to two years to monitor treatment effects and safety.
CONDITIONS
Brief Title
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Research Team
L
Li Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
